All In Biotech

Drug Trial Radar · NCT02328469

Aseptic Meningoencephalitis in Slovenia

Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia

Last checked: Nov 19, 2026Latest source record: May 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Jun 2014

Primary completion

Jun 2020

Study completion Jun 2020

Sponsor

Lead sponsor
University Medical Centre LjubljanaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Slovenian Research Agency; University of Ljubljana School of Medicine, Slovenia; Harvard University
First posted
Dec 31, 2014

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this study is: * to establish etiology of acute aseptic meningitis/meningoencephalitis in Slovenia * to assess the clinical course and outcome of tick-borne encephalitis and Lyme neuroborreliosis * to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with tick-borne encephalitis and Lyme neuroborreliosis

Conditions

  • Aseptic Meningitis

Interventions

  • symptomatic therapyDrug

    patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline

  • Ceftriaxone or DoxycyclineDrug

    beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days

  • questionnaireOther

    Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.

  • AcyclovirDrug

    Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in selected clinical parameters in patients with acute aseptic meningitis/meningoencephalitisTime frame: at enrollment and during 12 months follow-up
  2. Changes in selected laboratory parameters in patients with acute aseptic meningitis/meningoencephalitisTime frame: at enrollment and during 12 months follow-up
  3. Changes in selected microbiologic parameters in patients with acute aseptic meningitis/meningoencephalitisTime frame: at enrollment and during 12 months follow-up

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia

    Ljubljana, Slovenia · Recruiting

  • UMC Ljubljana, Department of Infectious Diseases

    Ljubljana, Slovenia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.